RZLT Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 13:34):

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States...

Stats
Today's Volume	234 444
Average Volume	379 140
Market Cap	112.56M
EPS	$0 ( 2024-02-09 )
Next earnings date	( $-0.270 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.55
ATR14	$0.0170 (0.61%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Roberts Brian Kenneth	Buy	500	Common Shares
2022-07-22	Handok, Inc.	Buy	3 157 895	Common Shares
2021-10-15	Handok, Inc.	Buy	769 231	Common Shares
2024-03-15	Evans Daron	Buy	20 000	Common Shares
2024-03-14	Roberts Brian Kenneth	Buy	10 000	Common Shares

INSIDER POWER
100.00
Last 96 transactions
Buy: 107 305 216 \| Sell: 58 571 575

Volume Correlation

Long: 0.02 (neutral)

Short: -0.13 (neutral)

Signal:(49.357) Neutral

Rezolute, Inc. Correlation

10 Most Positive Correlations
SY	0.885
RNA	0.884
ANDE	0.879
PIRS	0.873
EYEN	0.872
BRACU	0.87
ZGNX	0.87
PAE	0.865
MLAC	0.865
PALT	0.865

10 Most Negative Correlations
TRMK	-0.872
CFV	-0.866
BCYC	-0.864
AYTU	-0.851
GOOD	-0.849
GMII	-0.847
TUEM	-0.843
NAKD	-0.842
RBB	-0.837
DTSS	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rezolute, Inc. Correlation - Currency/Commodity

-0.10
( neutral )

-0.33
( neutral )

0.00
( neutral )

-0.59
( weak negative )

0.25
( neutral )

Rezolute, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-382 000 (0.00 %)
EPS:	$-1.010

Q2	2024
Revenue:	$0
Gross Profit:	$-10 000.00 (0.00 %)
EPS:	$-0.270

Q1	2024
Revenue:	$0
Gross Profit:	$-10 000.00 (0.00 %)
EPS:	$-0.280

Q4	2023
Revenue:	$0
Gross Profit:	$-128 000 (0.00 %)
EPS:	$-0.250

Financial Reports:

No articles found.

Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.